FindTrial
Sign In

6MHP

BIOLOGICAL7 trials

Sponsors

University of Virginia, Craig L Slingluff, Jr

Conditions

Intraocular MelanomaMelanomaMelanoma (Skin)Ocular MelanomaUveal Melanoma

Early Phase 1

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
TerminatedNCT02382549
Craig L Slingluff, JrMelanoma
Start: 2016-04-30End: 2022-02-28Updated: 2023-12-12

Phase 1

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
CompletedNCT00089219
University of VirginiaIntraocular Melanoma, Melanoma (Skin)
Start: 2003-07-31Updated: 2014-11-20
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
TerminatedNCT02385669
Craig L Slingluff, JrMelanoma
Start: 2015-04-30End: 2019-09-18Updated: 2020-05-05
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
TerminatedNCT02425306
Craig L Slingluff, JrMelanoma
Start: 2015-05-12End: 2018-01-08Updated: 2023-10-30
Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
CompletedNCT02515227
Craig L Slingluff, JrMelanoma
Start: 2016-10-06End: 2020-03-14Updated: 2023-08-25
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
CompletedNCT03617328
Craig L Slingluff, JrMelanoma
Start: 2018-11-13End: 2024-01-19Updated: 2024-02-06
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
CompletedNCT04364230
Craig L Slingluff, JrMelanoma, Ocular Melanoma, Uveal Melanoma
Start: 2020-09-28End: 2024-03-14Updated: 2024-07-16

Related Papers

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).
2026-03-03
Adjuvant polypeptide vaccines for high-risk uveal melanoma.
Journal of Clinical Oncology2023-06-013 citations
1474 Cancer vaccine plus PD-1 blockade promotes infiltration of melanoma metastases by vaccine-induced T lymphocytes
2022-11-011 citations
388 A trial to evaluate the safety, immunogenicity, and clinical activity of a helper peptide vaccine plus PD-1 blockade (Mel64, PATHVACS: PD-1 antibody and T-helper vaccine and correlative studies)
Regular and Young Investigator Award Abstracts2021-11-012 citations
Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
Journal for ImmunoTherapy of Cancer2020-04-0132 citations
Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies.
2017-08-297 citations
A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes
Journal for ImmunoTherapy of Cancer2014-01-0123 citations